Medpace Holdings, Inc. (NASDAQ:MEDP) Shares Purchased by Townsquare Capital LLC

Townsquare Capital LLC boosted its holdings in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 7.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 12,387 shares of the company’s stock after purchasing an additional 806 shares during the period. Townsquare Capital LLC’s holdings in Medpace were worth $4,115,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in MEDP. Distillate Capital Partners LLC increased its stake in Medpace by 2.7% in the 4th quarter. Distillate Capital Partners LLC now owns 44,317 shares of the company’s stock valued at $14,723,000 after buying an additional 1,155 shares during the period. Grandeur Peak Global Advisors LLC increased its stake in shares of Medpace by 0.6% during the fourth quarter. Grandeur Peak Global Advisors LLC now owns 28,265 shares of the company’s stock worth $9,390,000 after acquiring an additional 165 shares during the period. Covestor Ltd raised its holdings in Medpace by 9.3% during the fourth quarter. Covestor Ltd now owns 655 shares of the company’s stock worth $218,000 after purchasing an additional 56 shares in the last quarter. Capital Fund Management S.A. raised its holdings in Medpace by 73.9% during the fourth quarter. Capital Fund Management S.A. now owns 24,758 shares of the company’s stock worth $8,225,000 after purchasing an additional 10,520 shares in the last quarter. Finally, Bessemer Group Inc. lifted its position in Medpace by 15.0% in the fourth quarter. Bessemer Group Inc. now owns 576,044 shares of the company’s stock valued at $191,379,000 after purchasing an additional 75,275 shares during the period. Hedge funds and other institutional investors own 77.98% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on MEDP. Mizuho cut their target price on Medpace from $400.00 to $355.00 and set an “outperform” rating for the company in a research note on Wednesday, April 9th. TD Cowen cut Medpace from a “buy” rating to a “hold” rating and cut their price objective for the stock from $370.00 to $328.00 in a research report on Monday. Robert W. Baird upped their price target on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research note on Monday, January 27th. Leerink Partners initiated coverage on shares of Medpace in a research note on Monday, March 24th. They issued a “market perform” rating and a $330.00 price objective for the company. Finally, Truist Financial lowered their target price on shares of Medpace from $347.00 to $333.00 and set a “hold” rating on the stock in a research report on Thursday, April 10th. Ten analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat.com, Medpace currently has a consensus rating of “Hold” and an average target price of $357.50.

Medpace Price Performance

Shares of NASDAQ MEDP opened at $305.28 on Tuesday. The firm’s 50-day moving average is $322.58 and its two-hundred day moving average is $334.29. Medpace Holdings, Inc. has a 12-month low of $272.00 and a 12-month high of $459.77. The company has a market capitalization of $9.23 billion, a PE ratio of 24.17, a price-to-earnings-growth ratio of 3.81 and a beta of 1.46.

Medpace (NASDAQ:MEDP) last announced its earnings results on Monday, February 10th. The company reported $3.67 EPS for the quarter, beating analysts’ consensus estimates of $2.96 by $0.71. Medpace had a return on equity of 51.48% and a net margin of 19.17%. On average, analysts forecast that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.